• Data are no longer planned to be summarized or evaluated by study phase. • In regard to safety analysis only relevant safety data will be summarized and all will be listed . Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 23 of 24 04MAY2018 7. REFERENCES 1. ICH-E9 Statistical Principals for Clinical Trials, September 1998 2. ICH-E3 Stru cture and Content of Clinical Study Report, July 1996 3. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2004;15:257- 60 4. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune- related response criteria. Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15:7412- 20 Aduro Biotech, Inc. CONFIDENTIAL Protocol ADU -CL-02 Final Version 1 Page 24 of 24 04MAY2018 8. L IST OF TABLES, FIGURES AND LISTINGS FOR FINAL ANALYSIS All tables, listings and figures will be numbered according to the ICH -E3 Guideline2. The complete table of contents of data tables, figures and listings can be found in the mock tables, figures, and listings document .